MCID: MLG070
MIFTS: 23

Malignant Iris Melanoma

Categories: Eye diseases, Neuronal diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Malignant Iris Melanoma

MalaCards integrated aliases for Malignant Iris Melanoma:

Name: Malignant Iris Melanoma 12 14
Malignant Melanoma of Iris 12
Melanoma of the Iris 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6994
NCIt 47 C9088
SNOMED-CT 64 255012009
UMLS 69 C0346373

Summaries for Malignant Iris Melanoma

MalaCards based summary : Malignant Iris Melanoma, also known as malignant melanoma of iris, is related to iris spindle cell melanoma and c-p angle neurinoma. An important gene associated with Malignant Iris Melanoma is S100B (S100 Calcium Binding Protein B), and among its related pathways/superpathways is Ca, cAMP and Lipid Signaling. The drugs Peginterferon alfa-2b and Sunitinib have been mentioned in the context of this disorder. Affiliated tissues include eye and liver, and related phenotype is normal.

Related Diseases for Malignant Iris Melanoma

Graphical network of the top 20 diseases related to Malignant Iris Melanoma:



Diseases related to Malignant Iris Melanoma

Symptoms & Phenotypes for Malignant Iris Melanoma

MGI Mouse Phenotypes related to Malignant Iris Melanoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 8.8 CCND1 S100A1 S100B

Drugs & Therapeutics for Malignant Iris Melanoma

Drugs for Malignant Iris Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
2
Sunitinib Approved, Investigational Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
3
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
4
Lenalidomide Approved Phase 2 191732-72-6 216326
5
Cediranib Investigational Phase 2 288383-20-0 9933475
6
Maleic acid Experimental Phase 2 110-16-7 444266
7 Protein Kinase Inhibitors Phase 2
8 Angiogenesis Inhibitors Phase 2,Phase 1
9 Angiogenesis Modulating Agents Phase 2,Phase 1
10 Anti-Bacterial Agents Phase 2
11 Anti-Infective Agents Phase 2
12 Antiviral Agents Phase 2
13 Immunosuppressive Agents Phase 2
14 Interferon-alpha Phase 2
15 interferons Phase 2
16 Adjuvants, Immunologic Phase 2,Phase 1
17 Vaccines Phase 2,Phase 1
18 Carboxymethylcellulose Sodium Phase 2
19 Cathartics Phase 2
20 Flt3 ligand protein Phase 2
21 Gastrointestinal Agents Phase 2
22 Interferon Inducers Phase 2
23 Laxatives Phase 2
24 Poly I-C Phase 2
25 Poly ICLC Phase 2
26 Protective Agents Phase 2
27 Radiation-Protective Agents Phase 2
28 Alkylating Agents Phase 2,Phase 1
29 Antirheumatic Agents Phase 2
30
Dacarbazine Approved, Investigational Phase 1 4342-03-4 5351166
31
Temozolomide Approved, Investigational Phase 1 85622-93-1 5394
32
Entinostat Investigational Phase 1 209783-80-2
33 CPG-oligonucleotide Phase 1
34 Freund's Adjuvant Phase 1
35 Histone Deacetylase Inhibitors Phase 1
36 Liver Extracts Phase 1
37 Cola Nutraceutical Phase 1

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma Completed NCT00243061 Phase 2 cediranib maleate
2 PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Completed NCT00238329 Phase 2 thalidomide
3 CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma Active, not recruiting NCT02129075 Phase 2
4 Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma Terminated NCT00482911 Phase 2 cyclophosphamide;lenalidomide;sunitinib malate
5 Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00471471 Phase 1
6 Vaccine Therapy in Treating Patients With Advanced Melanoma Completed NCT00705640 Phase 1
7 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
8 Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma Active, not recruiting NCT01005472 Phase 1 sunitinib malate;temozolomide

Search NIH Clinical Center for Malignant Iris Melanoma

Genetic Tests for Malignant Iris Melanoma

Anatomical Context for Malignant Iris Melanoma

MalaCards organs/tissues related to Malignant Iris Melanoma:

39
Eye, Liver

Publications for Malignant Iris Melanoma

Articles related to Malignant Iris Melanoma:

id Title Authors Year
1
Ultrasound biomicroscopy in management of malignant iris melanoma. ( 12742854 )
2003

Variations for Malignant Iris Melanoma

Expression for Malignant Iris Melanoma

Search GEO for disease gene expression data for Malignant Iris Melanoma.

Pathways for Malignant Iris Melanoma

Pathways related to Malignant Iris Melanoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.72 S100A1 S100B

GO Terms for Malignant Iris Melanoma

Biological processes related to Malignant Iris Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to glucocorticoid GO:0051384 8.62 CCND1 S100B

Molecular functions related to Malignant Iris Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 calcium-dependent protein binding GO:0048306 8.96 S100A1 S100B
2 S100 protein binding GO:0044548 8.62 S100A1 S100B

Sources for Malignant Iris Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....